Back
Full-text
Journal article

No association of complement mannose-binding lectin deficiency with cardiovascular disease in patients with Systemic Lupus Erythematosus.

  • Kieninger-Gräfitsch A Division of Internal Medicine and Clinical Immunology Lab, Department of Biomedicine, University Hospital and University, Basel, Switzerland. a.kieninger@gmx.net.
  • Vogt S Division of Internal Medicine and Clinical Immunology Lab, Department of Biomedicine, University Hospital and University, Basel, Switzerland.
  • Ribi C Department of Immunology and Allergy, University Hospital, Lausanne, Switzerland.
  • Dubler D Division of Internal Medicine and Clinical Immunology Lab, Department of Biomedicine, University Hospital and University, Basel, Switzerland.
  • Chizzolini C Department of Internal Medicine Specialties, Clinical Immunology and Allergy, University Hospital and School of Medicine, Geneva, Switzerland.
  • Huynh-Do U Department of Nephrology and Hypertension, University Hospital, Bern, Switzerland.
  • Osthoff M Division of Internal Medicine and Clinical Immunology Lab, Department of Biomedicine, University Hospital and University, Basel, Switzerland.
  • Trendelenburg M Division of Internal Medicine and Clinical Immunology Lab, Department of Biomedicine, University Hospital and University, Basel, Switzerland.
Show more…
  • 2020-03-01
Published in:
  • Scientific reports. - 2020
Adult
Age Factors
Female
Humans
Hypertension
Longitudinal Studies
Lupus Erythematosus, Systemic
Male
Mannose-Binding Lectin
Metabolism, Inborn Errors
Middle Aged
Risk Factors
English Cardiovascular (CV) morbidity is the major cause of death in patients with Systemic Lupus Erythematosus (SLE). Previous studies on mannose-binding lectin (MBL) gene polymorphisms in SLE patients suggest that low levels of complement MBL are associated with cardiovascular disease (CVD). However, as large studies on MBL deficiency based on resulting MBL plasma concentrations are lacking, the aim of our study was to analyze the association of MBL concentrations with CVD in SLE patients. Plasma MBL levels SLE patients included in the Swiss SLE Cohort Study were quantified by ELISA. Five different CV organ manifestations were documented. Of 373 included patients (85.5% female) 62 patients had at least one CV manifestation. Patients with MBL deficiency (levels below 500 ng/ml or 1000 ng/ml) had no significantly increased frequency of CVD (19.4% vs. 15.2%, P = 0.3 or 17.7% vs. 15.7%, P = 0.7). After adjustment for traditional CV risk factors, MBL levels and positive antiphospholipid serology (APL+) a significant association of CVD with age, hypertension, disease duration and APL+ was demonstrated. In our study of a large cohort of patients with SLE, we could not confirm previous studies suggesting MBL deficiency to be associated with an increased risk for CVD.
Language
  • English
Open access status
gold
Identifiers
Persistent URL
https://sonar.ch/global/documents/67073
Statistics
Document views: 44 File downloads:
  • Full-text: 0